Cancer stem cells have become the new target of chemotherapy with specific cell marker. CD133 is shown to be highly expressed in glioma cancer stem cells. In this study, a drug delivery system is designed to target CD...Cancer stem cells have become the new target of chemotherapy with specific cell marker. CD133 is shown to be highly expressed in glioma cancer stem cells. In this study, a drug delivery system is designed to target CD133 by a seven amino acid peptide （TR peptide）, which is capable to specifically bind to CD 133. First, TR was conjugated to DSPE-PEG and coumarin-6 was loaded into the DSPE-PEG micelles. Then fluorescence-activated cell sorting （FACS） and tumorsphere culture were conducted to isolate cancer stern cells in C6 cells. The enhanced uptake of micelles was observed by confocal microscopy and flow cytometry, suggesting that TR peptide-modified micelles may exhibit better anti-cancer efficacy by targeting CD133^＋ glioma stem cells.In conclusion, TR peptide-modified micelles may provide new strategy to achieve enhanced specificity to CD 133^＋ glioma stem cells.展开更多
基金The Key Program of National Science Foundation(Grant No.81130059)the National Basic Research Program of China(Grant No.973 program,2013CB932501)
文摘Cancer stem cells have become the new target of chemotherapy with specific cell marker. CD133 is shown to be highly expressed in glioma cancer stem cells. In this study, a drug delivery system is designed to target CD133 by a seven amino acid peptide （TR peptide）, which is capable to specifically bind to CD 133. First, TR was conjugated to DSPE-PEG and coumarin-6 was loaded into the DSPE-PEG micelles. Then fluorescence-activated cell sorting （FACS） and tumorsphere culture were conducted to isolate cancer stern cells in C6 cells. The enhanced uptake of micelles was observed by confocal microscopy and flow cytometry, suggesting that TR peptide-modified micelles may exhibit better anti-cancer efficacy by targeting CD133^＋ glioma stem cells.In conclusion, TR peptide-modified micelles may provide new strategy to achieve enhanced specificity to CD 133^＋ glioma stem cells.
